This publication on cutting red tape analyses how administrative simplification is used as a regulatory quality tool to review and reduce administrative and regulatory procedures.
English, , 4,891kb
The 2009 report presents indicators of the development of the regulatory management systems used in OECD countries to improve the quality of regulation.
Indonesia’s infrastructure is in poor shape, having suffered from protracted under-investment since the Asian financial crisis of the late 1990s, and constraints growth potential.
In the current circumstances of weak recovery, high unemployment and constrained room for manoeuvre by macro-economic policies, a robust regulatory environment is key to return to a stronger, fairer and sustainable growth path, said OECD Secretary-General.
In light of the recent financial crisis and the pressing social, environmental and economic challenges facing governments today, this conference offered a timely opportunity to redefine the agenda for regulatory policy with a forward-looking perspective.
In this paper the recently updated product market regulation (PMR) indicators are extended beyond OECD member countries - including accession and enhanced engagement countries.
English, , 1,391kb
Credit ratings provide an opinion on the relative ability and willingness of parties with debt obligations to meet financial commitments. They have three functions: to measure the credit risk of the issuer, to provide a means of comparison and to provide a common standard. The credit rating market is a natural oligopoly, with three Credit Rating Agencies (CRAs) accounting for more than 90% of the market. The recent financial crisis
How can governments reap the potential benefits of public-private partnerships (PPPs) in the provision of infrastructure?
Open markets will be necessary for a sustained economic recovery. This report recommends that governments continue to resist protectionist pressures and work towards a level playing field for trade.
English, Excel, 1,834kb
Practices that may harm competition in the pharmaceutical sector have emerged as important and controversial issues in recent years. This proceedings examine the nature of competition between generic and branded products in the pharmaceutical sector, as well as the effects on competition of agreements to delay the entry of generics on the market. It includes an analytical note by the staff of the United States Federal Trade